Dipexium Pharmaceuticals
White Plains
About Dipexium Pharmaceuticals
Dipexium Pharmaceuticals operates as a biopharmaceutical company that develops and commercializes, pexiganan, a small peptide anti-infective agent. It provides Locilex, a small peptide topical antibiotic for the treatment of mild and moderate skin infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds, and nasal colonization of methicillin-resistant staphylococcus aureus.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $6.9M
- Funding stage: M&A
- Last round: Series Unknown (Jul 2013)
- Ticker: nasdaq:DPRX
- Website: dipexiumpharmaceuticals.com
- Phone: +1 914-949-3898
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/dipexium-pharmaceuticals-1730612 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.